BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Study Details
Study Description
Brief Summary
The goal of a phase Ib clinical trial is to find the doses of drugs that are safe. Although BGJ398 has been given to patients safely on its own, it has never been given together with imatinib mesylate. In this study, we will test the safety of taking BGJ398 with imatinib mesylate. The investigators will learn this by closely checking for side effects that the patient may experience. Side effects can be seen in laboratory studies, on physical examination, or by asking the patient.Once a dose has been determined to be safe, a larger Phase II study will be done in patients with advanced GIST who have never received any prior treatments.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: BGJ398 With Imatinib Mesylate BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days. |
Drug: BGJ398
Drug: Imatinib Mesylate
|
Outcome Measures
Primary Outcome Measures
- Phase Ib Study: Number of Participants With Dose-Limiting Toxicities [1 year]
The phase Ib will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy.
- Phase Ib Portion: Response Rate (RR) [32 weeks]
(CR+PR, RECIST 1.1) and by CHOI criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Secondary Outcome Measures
- Phase Ib Study: Response Rate (RR) [32 weeks]
defined by RECIST 1.1 criteria and by CHOI criteria,and by EORTC criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have pathologically confirmed GIST.
-
In the Phase Ib portion, must have locally advanced or metastatic GIST and have progressed on imatinib.
-
In the Phase II portion, patients must be newly diagnosed or imatinib treatment naïve in the advanced/metastatic setting. Prior adjuvant imatinib therapy is allowed as long as disease recurrence was documented ≥90 days after last dose of imatinib and imatinib has not yet been restarted.
-
Patients must be at least 18 years of age.
-
Disease must be measurable by RECIST 1.1.
-
ECOG Performance Status 0 or 1. Adequate renal, hepatic, and hematologic function as the following: Serum Creatinine ≤ 1.5 mg/dL, Total Serum Bilirubin ≤ 1.5 x upper limit of normal (ULN) unless due to Gilbert's Disease, Serum AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor), ANC ≥ 1500/mm3, Platelets ≥ 100,000/mm3, and hemoglobin ≥ 10g/dL.
-
Patients of childbearing potential must have a negative blood pregnancy test within 14 days of treatment. Patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drug.
-
Patient must have adequate cardiac function (left ventricular ejection fraction (LVEF) ≥50% as determined by a multigated acquisition (MUGA) scan or echocardiogram; and QTc interval ≤480 ms by Fridericia's formula (QTcF).
-
Patient must be able to take oral medications.
-
Patients must sign an informed consent document.
Exclusion Criteria:
-
For phase I, prior intolerance to imatinib at a dose of 400 mg daily.
-
For phase II, any receipt of cytotoxic, biologic, or immune therapy aimed to treat GIST except for adjuvant imatinib systemic therapy that concluded at least 90 days prior to registration. For Phase I, patients are eligible regardless of prior therapy.
-
Chronic liver disease (e.g., cirrhosis)
-
Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C infection.
-
Patients have a history or current evidence of Central Serous Retinopathy (CSR) or retinal vein occlusion (RVO) or major predisposing factors to CSR or RVO (e.g. uncontrolled glaucoma or ocular hypertension) in the opinion of the study ophthalmologist.
-
History of retinal degenerative disease
-
Active corneal disorder or keratopathy (e.g. corneal abrasion, bullous keratopathy)
-
Severe and/or uncontrolled medical disease, including:
-
Uncontrolled diabetes mellitus (A1c >8)
-
Chronic Kidney Disease Stage III or higher (Creatinine Clearance <60mL/min/m2 by Modified Diet in Renal Disease (MDRD) calculation)
-
Active, uncontrolled infection Known active brain metastasis unless they have been treated and shown documented radiographic stability for 28 days.
-
Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis).
-
Patients have clinically significant cardiovascular disease, including any of the following
-
Any history of acute coronary syndrome including myocardial infarction, stable or unstable angina, CABG, coronary angioplasty or stenting or known obstructive coronary artery disease.
-
Symptomatic chronic heart failure (New York Heart Association Criteria, Class II-IV)
-
Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
-
Any history of thrombotic cerebrovascular accident or other arterial thrombosis
-
Uncontrolled arterial hypertension (systolic blood pressure >155 mmHg or diastolic >95 mmHg) despite appropriate medical therapy.
-
History and/or current evidence of uncontrolled endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis, etc.
-
Impairment of gastrointestinal function or gastrointestinal disease (e.g., uncontrolled ulcerative disease; uncontrolled nausea, vomiting, diarrhea; chronic malabsorption syndrome).
-
Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure.
-
Women who are pregnant or lactating.
-
Sexually active males, unless they use a condom during intercourse while taking the drug and for 15 days after stopping treatment. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
-
Patients with any significant history of non-adherence to medical regimens or with inability to grant reliable informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02115 |
| 2 | Memoral Sloan Kettering Cancer Center | Basking Ridge | New Jersey | United States | |
| 3 | Memorial Sloan Kettering Cancer Center @ Suffolk | Commack | New York | United States | 11725 |
| 4 | Memorial Sloan Kettering Westchester | Harrison | New York | United States | 10604 |
| 5 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
| 6 | Memorial Sloan Kettering at Mercy Medical Center | Rockville Centre | New York | United States | |
| 7 | Md Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- Dana-Farber Cancer Institute
- M.D. Anderson Cancer Center
- University of Pittsburgh
Investigators
- Principal Investigator: William Tap, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- 14-140
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2 | Phase 1b, Dose Level -2 | Phase II |
|---|---|---|---|---|---|
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg | Phase II: BGJ398 75mg |
| Period Title: Overall Study | |||||
| STARTED | 3 | 8 | 1 | 3 | 1 |
| COMPLETED | 3 | 8 | 1 | 3 | 1 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2 | Phase 1b, Dose Level -2 | Phase II | Total |
|---|---|---|---|---|---|---|
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg | Phase II: BGJ398 75mg | Total of all reporting groups |
| Overall Participants | 3 | 8 | 1 | 3 | 1 | 16 |
| Age (years) [Median (Full Range) ] | ||||||
| Median (Full Range) [years] |
54
|
58.88
|
44
|
53
|
53
|
54
|
| Sex: Female, Male (Count of Participants) | ||||||
| Female |
0
0%
|
2
25%
|
0
0%
|
0
0%
|
1
100%
|
3
18.8%
|
| Male |
3
100%
|
6
75%
|
1
100%
|
3
100%
|
0
0%
|
13
81.3%
|
| Ethnicity (NIH/OMB) (Count of Participants) | ||||||
| Hispanic or Latino |
0
0%
|
1
12.5%
|
0
0%
|
0
0%
|
0
0%
|
1
6.3%
|
| Not Hispanic or Latino |
3
100%
|
6
75%
|
0
0%
|
3
100%
|
0
0%
|
12
75%
|
| Unknown or Not Reported |
0
0%
|
1
12.5%
|
1
100%
|
0
0%
|
1
100%
|
3
18.8%
|
| Race (NIH/OMB) (Count of Participants) | ||||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
2
25%
|
0
0%
|
0
0%
|
0
0%
|
2
12.5%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
1
33.3%
|
1
12.5%
|
0
0%
|
0
0%
|
0
0%
|
2
12.5%
|
| White |
2
66.7%
|
4
50%
|
1
100%
|
3
100%
|
0
0%
|
10
62.5%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
1
12.5%
|
0
0%
|
0
0%
|
1
100%
|
2
12.5%
|
| Region of Enrollment (Count of Participants) | ||||||
| United States |
3
100%
|
8
100%
|
1
100%
|
3
100%
|
1
100%
|
16
100%
|
Outcome Measures
| Title | Phase Ib Study: Number of Participants With Dose-Limiting Toxicities |
|---|---|
| Description | The phase Ib will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy. |
| Time Frame | 1 year |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2 | Phase 1b, Dose Level -2 |
|---|---|---|---|---|
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg |
| Measure Participants | 3 | 8 | 1 | 3 |
| Count of Participants [Participants] |
3
100%
|
8
100%
|
1
100%
|
3
100%
|
| Title | Phase Ib Portion: Response Rate (RR) |
|---|---|
| Description | (CR+PR, RECIST 1.1) and by CHOI criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Time Frame | 32 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2 | Phase 1b, Dose Level -2 |
|---|---|---|---|---|
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg |
| Measure Participants | 3 | 8 | 1 | 3 |
| Partial Response/PR |
1
33.3%
|
0
0%
|
0
0%
|
0
0%
|
| Stable Disease/SD |
2
66.7%
|
3
37.5%
|
0
0%
|
0
0%
|
| Progressive Disease/PD |
0
0%
|
3
37.5%
|
1
100%
|
3
100%
|
| Not reported due to withdrawn from study |
0
0%
|
2
25%
|
0
0%
|
0
0%
|
| Title | Phase Ib Study: Response Rate (RR) |
|---|---|
| Description | defined by RECIST 1.1 criteria and by CHOI criteria,and by EORTC criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Time Frame | 32 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2 | Phase 1b, Dose Level -2 |
|---|---|---|---|---|
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg |
| Measure Participants | 3 | 8 | 1 | 3 |
| Progressive Disease/PD |
1
33.3%
|
2
25%
|
0
0%
|
3
100%
|
| Stable Disease/SD |
2
66.7%
|
4
50%
|
1
100%
|
0
0%
|
| Not reported due to withdrawn from study |
0
0%
|
2
25%
|
0
0%
|
0
0%
|
Adverse Events
| Time Frame | 1 year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||
| Arm/Group Title | Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2: | Phase 1b, Dose Level -2 | Phase II | |||||
| Arm/Group Description | Phase 1b, Dose Level -1: BGJ398 50 mg | Phase 1b, Dose Level 1: BGJ398 75 mg | Phase 1b, Dose Level 2: BGJ398 100 mg | Phase 1b, Dose Level -2: BGJ398 25 mg | Phase II: BGJ398 75mg | |||||
All Cause Mortality |
||||||||||
| Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2: | Phase 1b, Dose Level -2 | Phase II | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 2/3 (66.7%) | 3/8 (37.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
Serious Adverse Events |
||||||||||
| Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2: | Phase 1b, Dose Level -2 | Phase II | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 2/3 (66.7%) | 7/8 (87.5%) | 1/1 (100%) | 3/3 (100%) | 0/1 (0%) | |||||
| Cardiac disorders | ||||||||||
| Myocardial Infarction | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Gastrointestinal disorders | ||||||||||
| Abdominal Pain | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Intra-Abdominal Bleeding | 0/3 (0%) | 0/8 (0%) | 1/1 (100%) | 0/3 (0%) | 0/1 (0%) | |||||
| General disorders | ||||||||||
| Fatigue | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Investigations | ||||||||||
| CPK increased | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Ejection Fraction decreased | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Lipase Increased | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Musculoskeletal and connective tissue disorders | ||||||||||
| Back Pain | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||
| Dyspnea | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Pleural Effusion | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Vascular disorders | ||||||||||
| Hypertension | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
Other (Not Including Serious) Adverse Events |
||||||||||
| Phase 1b, Dose Level -1 | Phase 1b, Dose Level 1 | Phase 1b, Dose Level 2: | Phase 1b, Dose Level -2 | Phase II | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | 8/8 (100%) | 1/1 (100%) | 3/3 (100%) | 1/1 (100%) | |||||
| Blood and lymphatic system disorders | ||||||||||
| Anemia | 3/3 (100%) | 3/8 (37.5%) | 1/1 (100%) | 0/3 (0%) | 1/1 (100%) | |||||
| Cardiac disorders | ||||||||||
| Chest Pain - Cardiac | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Myocardial infarction | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Sinus bradycardia | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Endocrine disorders | ||||||||||
| Hypothyroidism | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Eye disorders | ||||||||||
| Flashing Lights | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Blurred Vision | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Dry Eye | 0/3 (0%) | 2/8 (25%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Periorbital edema | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 1/1 (100%) | |||||
| Watering eyes | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 1/1 (100%) | |||||
| Gastrointestinal disorders | ||||||||||
| Abdominal pain | 3/3 (100%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 1/1 (100%) | |||||
| Constipation | 1/3 (33.3%) | 3/8 (37.5%) | 1/1 (100%) | 0/3 (0%) | 0/1 (0%) | |||||
| Diarrhea | 1/3 (33.3%) | 3/8 (37.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Dry Mouth | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Dyspepsia | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Vomiting | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Anorexia | 0/3 (0%) | 2/8 (25%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Ascites | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Bloating | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Nausea | 0/3 (0%) | 2/8 (25%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Gastritis | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| General disorders | ||||||||||
| Edema Limbs | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Fatigue | 2/3 (66.7%) | 5/8 (62.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Pain | 1/3 (33.3%) | 0/8 (0%) | 1/1 (100%) | 0/3 (0%) | 0/1 (0%) | |||||
| Fever | 0/3 (0%) | 0/8 (0%) | 1/1 (100%) | 0/3 (0%) | 0/1 (0%) | |||||
| Non-cardiac chest pain | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 1/1 (100%) | |||||
| Investigations | ||||||||||
| AST Elevated | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 2/3 (66.7%) | 0/1 (0%) | |||||
| CPK Increased | 3/3 (100%) | 4/8 (50%) | 0/1 (0%) | 1/3 (33.3%) | 1/1 (100%) | |||||
| Creatinine Increased | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Decreased TSH | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Electrocardiogram QT corrected interval prolonged | 1/3 (33.3%) | 0/8 (0%) | 1/1 (100%) | 1/3 (33.3%) | 1/1 (100%) | |||||
| Lipase Increased | 2/3 (66.7%) | 3/8 (37.5%) | 0/1 (0%) | 1/3 (33.3%) | 1/1 (100%) | |||||
| Alanine aminotransferase increased | 1/3 (33.3%) | 0/8 (0%) | 1/1 (100%) | 0/3 (0%) | 0/1 (0%) | |||||
| Alkaline phosphatase increased | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Blood bilirubin increased | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Serum amylase increased | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Weight gain | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Weight loss | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Ejection fraction decreased | 0/3 (0%) | 0/8 (0%) | 1/1 (100%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Metabolism and nutrition disorders | ||||||||||
| Hyperglycemia | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Hyperkalemia | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Hyperphosphatemia | 2/3 (66.7%) | 1/8 (12.5%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Hypoalbuminemia | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 1/1 (100%) | |||||
| Hypocalcemia | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 1/1 (100%) | |||||
| Musculoskeletal and connective tissue disorders | ||||||||||
| Back Pain | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Myalgia | 1/3 (33.3%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Muscle weakness lower limb | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Nervous system disorders | ||||||||||
| Dysgeusia | 0/3 (0%) | 2/8 (25%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Memory Impairment | 0/3 (0%) | 2/8 (25%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Headache | 0/3 (0%) | 0/8 (0%) | 0/1 (0%) | 1/3 (33.3%) | 0/1 (0%) | |||||
| Psychiatric disorders | ||||||||||
| Anxiety | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||
| Sleep Apnea | 1/3 (33.3%) | 0/8 (0%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Cough | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Dyspnea | 0/3 (0%) | 3/8 (37.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Epistaxis | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Pleural effusion | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Skin and subcutaneous tissue disorders | ||||||||||
| Dry Skin | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Palmar-plantar erythrodysesthesia syndrome | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Skin hyperpigmentation | 0/3 (0%) | 1/8 (12.5%) | 0/1 (0%) | 0/3 (0%) | 0/1 (0%) | |||||
| Vascular disorders | ||||||||||
| Hypertension | 1/3 (33.3%) | 2/8 (25%) | 1/1 (100%) | 1/3 (33.3%) | 1/1 (100%) | |||||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. William Tap, MD |
|---|---|
| Organization | Memorial Sloan Kettering Cancer Center |
| Phone | 646-888-4163 |
| tapw@mskcc.org |
- 14-140